<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124850</url>
  </required_header>
  <id_info>
    <org_study_id>VRXP-A106</org_study_id>
    <nct_id>NCT02124850</nct_id>
  </id_info>
  <brief_title>A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab</brief_title>
  <official_title>A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With Cetuximab Plus Motolimod and With Cetuximab Plus Motolimod Plus Nivolumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol VRXP-A106 will enroll patients with Stage II-IVA head and neck cancer patients who
      will be treated with surgical resection. Cetuximab and motolimod (Cohort 1); and cetuximab,
      motolimod, and nivolumab (Cohort 2) will be administered for a 3-4 week period before
      surgery. The primary objective of the study is to determine the extent to which the
      administration of neoadjuvant motolimod plus cetuximab and motolimod plus cetuximab and
      nivolumab modulates immune biomarkers (NK, mDC and T cell activation as well as tumor
      infiltration and serum cytokines) in peripheral blood and head and neck cancer tumors. An
      exploratory objective of the study is to assess whether modulation of biomarkers as described
      above can predict anti-tumor response.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 28, 2014</start_date>
  <completion_date type="Actual">October 31, 2016</completion_date>
  <primary_completion_date type="Actual">August 11, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in immune biomarkers including FcγR genotype, NK activation, tumor infiltration and serum cytokines, mDC, T cell activation, and tumor-antigen specific cytotoxic T lymphocyte induction.</measure>
    <time_frame>change from baseline to up to 4 weeks</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Anti-tumor response</measure>
    <time_frame>Change from baseline to pre-surgery</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Motolimod plus cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: motolimod plus cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Motolimod, cetuximab, and nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: motolimod, cetuximab, and nivolumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Motolimod</intervention_name>
    <arm_group_label>Motolimod plus cetuximab</arm_group_label>
    <arm_group_label>Motolimod, cetuximab, and nivolumab</arm_group_label>
    <other_name>VTX-2337</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Motolimod plus cetuximab</arm_group_label>
    <arm_group_label>Motolimod, cetuximab, and nivolumab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Motolimod, cetuximab, and nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated stage II, III, or IVA histologically or cytologically confirmed
             squamous cell carcinoma of the head and neck

          -  Primary tumors of the oral cavity, oropharynx, hypopharynx, or larynx

          -  Macroscopic complete resection of the primary tumor must be planned

          -  Age ≥ 18 years

          -  ECOG performance status 0-1

          -  Adequate hematologic, renal and hepatic function

          -  Have signed written informed consent

        Exclusion Criteria:

          -  Subjects who fail to meet inclusion criteria

          -  Primary tumors of the sinuses, paranasal sinuses, or nasopharynx, or unknown primary
             tumors

          -  Prior severe infusion reaction to a monoclonal antibody

          -  Pregnancy or breastfeeding

          -  Evidence of distant metastasis

          -  Any other malignancy active within 5 years except for non-melanoma skin cancer or
             carcinoma in situ of the cervix, DCIS or LCIS of the breast

          -  Prior history of head and neck cancer

          -  Prior therapy with motolimod, nivolumab, or other agents targeting PD-1/PD-L1

          -  Prior therapy targeting the EGFR pathway

          -  Acute hepatitis, known HIV, or active uncontrolled infection

          -  Patients with active autoimmune disease

          -  History of uncontrolled cardiac disease within prior 6 months

          -  Uncontrolled peptic or gastric ulcer disease, or gastrointestinal bleeding within
             prior 6 months

          -  Active alcohol abuse or other illness or circumstance that carries a likelihood of
             inability to comply with study treatment and follow-up or otherwise compromise the
             study's objectives

          -  Treatment with a non-approved or investigational drug within 30 days prior to Day 1 of
             study treatment

          -  Live vaccine within 30 days of planned start of study therapy

          -  History of pneumonitis or interstitial lung disease

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to nivolumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amar Patel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>https://clincancerres.aacrjournals.org/content/clincanres/early/2017/11/28/1078-0432.CCR-17-0357.full.pdf</citation>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 22, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

